KZIA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	295 984
Average Volume	904 379
Market Cap	8.19M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.520
ATR14	$0.00800 (2.13%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

Volume Correlation

Long: 0.16 (neutral)

Short: 0.00 (neutral)

Signal:(46.279) Neutral

Kazia Therapeutics Correlation

10 Most Positive Correlations
PPTA	0.912
ACAB	0.901
OCAX	0.901
AVAC	0.898
EZGO	0.897
ALSK	0.894
ESCA	0.891
KVSA	0.888
BCOR	0.883
CNGL	0.882

10 Most Negative Correlations
VORB	-0.908
PEAR	-0.899
VIEW	-0.897
CFBK	-0.888
GNOG	-0.887
JG	-0.882
BLU	-0.88
HRMY	-0.877
JAN	-0.877
CUTR	-0.872

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kazia Therapeutics Correlation - Currency/Commodity

0.19
( neutral )

0.52
( weak )

0.00
( neutral )

0.60
( weak )

-0.15
( neutral )

Kazia Therapeutics Financials

Annual	2023
Revenue:	$555.00
Gross Profit:	$555.00 (100.00 %)
EPS:	$-0.110

Q4	2023
Revenue:	$555.00
Gross Profit:	$555.00 (100.00 %)
EPS:	$-0.0319

Q3	2023
Revenue:	$278.00
Gross Profit:	$278.00 (100.00 %)
EPS:	$-0.0154

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0933

Financial Reports:

No articles found.

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.